Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-18T19:19:30.909Z Has data issue: false hasContentIssue false
  • English
  • Français

Discinesias tardías y antipsicóticos: una revisión

Published online by Cambridge University Press:  12 May 2020

P-M. Llorca ,
I. Chereau ,
F-J. Bayle  and
C. Lancon
P-M. Llorca
Affiliation:
C.M.P.B., C. H. U. Clermont-Ferrand, rue Montalembert, BP 69, 63003 , Clermont-Ferrand cedex 1, Francia
I. Chereau
Affiliation:
C.M.P.B., C. H. U. Clermont-Ferrand, rue Montalembert, BP 69, 63003 , Clermont-Ferrand cedex 1, Francia
F-J. Bayle
Affiliation:
Universidad París V, René Descartes y CH Santa Ana, Servicio Hospitalario Universitario 1, rue Cabanis, 75674 , París cedex, Francia
C. Lancon
Affiliation:
Hospital Santa Margarita, 270 boulevard Sainte Marguerite, 13009 , Marsella, Francia
Get access

Resumen

Actualmente, la discinesia tardía (DT) es un problema clínico importante. La prevalencia media se estima en un 30%. La aparición de antipsicóticos ha abierto nuevos caminos. El perfil extrapiramidal de estas moléculas es más favorable que el de los neurolépticos convencionales. Para evaluar su potencial tanto profiláctico como curativo, revisamos las publicaciones acerca de cuatro de estos antipsicóticos atípicos: clozapina, risperidona, olanzapina y amisulprida. La clozapina parece inducir menos casos de DT que los neurolépticos convencionales, y tiene un efecto terapéutico específico. Sin embargo, el riesgo de agranulocitosis reduce la posibilidad de utilización. La risperidona parece ser una terapia efectiva, pero varios autores comunican casos de DT durante el tratamiento. Además, se necesitan estudios mayores y seguimientos más largos para confirmar la eficacia de la olanzapina y la amisulprida. Se necesitan aún otros estudios y observaciones antes de extraer una conclusión para estas nuevas acciones antipsicóticas atípicas. Sin duda son prometedoras, pero no podemos ignorar la noción de riesgo-beneficio; el control regular y la escucha a la experiencia subjetiva de los pacientes deben figurar en primer lugar en la elección de la terapia.

Keywords

Antipsicóticos atípicosDiscinesias tardíasClozapinaRisperidonaOlanzapinaAmisulprida
Type
Revisión
Information
European Psychiatry (Ed. Española) , Volume 9 , Issue 6 , September 2002 , pp. 359 - 369
Copyright
Copyright © European Psychiatric Association 2002

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

LlorcaP-M, ChereauI, BayleF-J, LanconC. Discinesias tardías y antipsicóticos: una revisiónEur Psychiatry2002; 17: 129-38.

References

Bibliografía

1Addington, DE, Toewes, JA, Addington, JM. Risperidone and tardive dyskinesia. J Clin Psychiatry 1995;56: 484–5.Google ScholarPubMed
2Ahmed, S, Chengappa, KN, Naidu, VR, Baker, RW, Parepally, H. Schooler, NR. Clozapine withdraval - emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1988;59: 472–7.CrossRefGoogle Scholar
3Almeida Osvaldo, P. Olanzapine for the treatment of tardive dyskinesia. J Clin Psychiatry 7July 1998,59: 380–1.CrossRefGoogle Scholar
4Anand, VS, Dewan, MJ. Withdraval-emergent dyskinesia in a patient on undergoing dosage reduction. Ann Clin Psychiatry 1996;8: 179–82.CrossRefGoogle Scholar
5Bassit, DP, Louza Neto, MR. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. Eur Arch Psychiatry Clin Neurosc (Germany) 1998,248(4): 209–11.CrossRefGoogle Scholar
6Beasley, CM, Dellva, MA, Tamura, RN, Morgenstem, H, Glazer, WM, Ferguson, K, Tollefson, GD. Randomised double blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174:23-30.CrossRefGoogle ScholarPubMed
7Boyer, P, Lecrubier, Y, Poech, AJ. Treatment of positive and negative symptoms: pharmacologic approaches. In: Andreasen, NC, editor. Schizophrenia: Positives and Negatives Symptoms and Syndromes, vol. 24. Basel, Switzerland: Karger; 2000. p. 152-74.Google Scholar
8Brecher, M. (abstract P- 15-1)Long -term safety of risperidone. Eur Neuropsychopharmacol 1996;6(Suppl. 3):170.CrossRefGoogle Scholar
9Brecher, M, Jeste, D, Okamoto, A. Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year, Presented at the 37th Annual Meeting of the American college of neuropsychopharmacology. Puerto Rico: San Juan, Dec. 14-18, 1998.Google Scholar
10Buzan, RD. Risperidone-induced tardive dyskinesia. Am J Psychiatry 1996;153: 734–5.Google ScholarPubMed
11Casey, DE. Effects of clozapine therapy in schizophrenie individuals at risk for tardive dyskinesia. Clozapine: a treatment option to be realized. J Clin Psychiatry 1998;59(Suppl 3): 31–7.Google Scholar
12Casey, DE. Tardive dyskinesia and atypical drugs. Schizophr Res 1999;35:S6l-6.CrossRefGoogle Scholar
13Chong Siow-Ann, M, Remington, G, Tan, C. Risperidone treatment of tardive dyskinesia and dystonia. J Clin Psychiatry 1999;60(5): 340–1.CrossRefGoogle Scholar
14Chouinard, G. Effects of risperidone in Tardive Dyskinesia: Analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol 1995;15(Suppl. l):36-44.CrossRefGoogle ScholarPubMed
15Cookell, AJ, Spencer, CM, Benfield, P. Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996;6: 237–56.CrossRefGoogle Scholar
16Dalery, J, d'Amato, T. La schizophrénie, recherches actuelles et perspectives. Masson; 1999.Google Scholar
17Daniel, DG, Smith, K, Hyde, T, Egan, M. (letter) Neurolepticinduced tardive dyskinesia. Am J Psychiatry 1996;153: 734-734.Google Scholar
18Danion, JM, Rein, W, Fleurot, O. Improvement of schizophrenic patients with primary negative symptoms treated with Amisulpride. Am J Psychiatry 1999;156(4):6l0-6.Google ScholarPubMed
19Factor, SA, Friedman, JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12: 483–96.CrossRefGoogle ScholarPubMed
20Gerlach, J. New anti psychotics: classification, efficacy and adverse effects. Schizophr Bull 1991;17:289-309.CrossRefGoogle Scholar
21Glazer, W. Review of the incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61(suppl. 4):15-20.Google ScholarPubMed
22Glazer, W. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000;6l (Suppl. 4):21-6.Google Scholar
23Jeste, DV, Wyatt, RJ. Tardive dyskinesia: Reversible and persistent. Arch Gen Psychiatry 1979;36(5): 585–90.CrossRefGoogle ScholarPubMed
24Jeste, DV, Lacro, JP, Bailey, A, Rockwell, E, Harris, MJ, Caligiuri, MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999,47: 716–9.CrossRefGoogle ScholarPubMed
25Jolley, AG, Hirsch, SR, McRink, A, Manchanda, R. Trial of brief intermittent neuroleptic prophilaxis for selected schizophrenic outpatients: clinical out come at one year. Br Med J 1989;298: 985–90.CrossRefGoogle Scholar
26Kane, JM. Tardive dyskinesia. In: Jeste, DV, Wyatt, RJ, editors. Neuropsychiatric Movement Disorders. Washington, DC: American Psychiaric Press; 1984. p. 68–95.Google Scholar
27Kane, JM, Woermer, M, Lieberman, JA. Tardive dyskinesia: Prevalence, incidence, and risk factors. Psychopharmacology 1985,2(Suppl): 72–8.Google Scholar
28Kane, JM, Honigfeld, G, Singer, J. Clozapine for the treatment resistan schizophrenic: a double-blind comparison versus Chlopromazine/benztropine. Arch Gen Psychiatry 1988;45: 789–96.CrossRefGoogle Scholar
29Kane, JM, Woermer, MG, Pollak, S, Safferman, AZ, Lieberman, JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54: 327–30.Google ScholarPubMed
30Kane, JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom, FE, Kupfer, DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York: Raven press; 1995. p. 1485–96.Google Scholar
31Kane, JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry 1999;60(Suppl. 5): 43–7.Google ScholarPubMed
32Keck, P, McElroy, S, Strakowski, S, Soutullo, C. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry 2000;6l(Suppl. 4):33-8.Google Scholar
33Kopala, LC, Honer, GW. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol. 1994;14: 430–1.CrossRefGoogle Scholar
34Larach Walters, V, Zamboni Tognolini, R, Rueda, MH, Gallardo, H, Torres, R, Delisi, LE. Tardive dyskinesia (TD) review and report on severe TD cases treated with clozapine, with 12,8 and 5 years of video follow-up. Schizophr Res 1997;28: 231–46.CrossRefGoogle Scholar
35Lieberman, JA, Saltz, BL, Johns, CA, Pollak, S, Borenstein, M, Kane, JM. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991;158: 503–10.CrossRefGoogle ScholarPubMed
36Littrell, KH, Johnson, CG, Littrel, S, Peabody, CD. Marked reduction of tardive dyskinesia with olanzapine. Arch Gen Psychiatry 1998;55: 279–80.CrossRefGoogle ScholarPubMed
37Loo, H, Porier-littre, MF, Rein, W, Fleurot, O. Amisulpride versus placebo in the long-term treatment of the negative symptomes of schizophrenia. Br J Psychiatry 1997;170:18–22.CrossRefGoogle Scholar
38Lykouras, L, Yannakis, R, Hatzimanolis, J, Christodoulou, GN. Two cases of risperidone-induced tardive dyskinesia and a review of the literature. Eur Psychiatry 1999;14:245-7.CrossRefGoogle Scholar
39Meltzer, HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99: 18-27.CrossRefGoogle ScholarPubMed
40Modestin, J, Stephan, PL, Erni, T, Umari, T. Prevalence of extra pyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophr Res 2000;42: 223–30.CrossRefGoogle Scholar
41Morgensten, H, Glazer, WM. Identifying risk-factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Arch Gen Psychiatry 1993;50: 723–33.Google Scholar
42Newton, JE, Cannon, DJ, Couch, L, Paige, SR, Reid, GM, Summers, BN. Effects of repeated drug holidays on serum haloperidol concentration, psychiatric symptoms and movement disorders patients. J Clin Psychiatry 1989;50: 132–5.Google Scholar
43O'Brien, J, Barber, R. Marked improvement in tardive dyskinesia following treatment with olanzapine in a elderly subject. Br J Psychiatry 1998;172: 186–9.CrossRefGoogle Scholar
44Owens, DGC. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55:29-35.Google ScholarPubMed
45Palliere-Martinot, ML, Lecubrier, Y, Martinot, JL, Aubin, F. Improvement of some schizophrenia deficit symptoms with low doses of amisulpride. Am J Psychiatry 1995;152: 130–3.Google Scholar
46Peacock, L, Solgaard, T, Lublin, H, Gerlach, J. Clozapine versus typical anti psychotic: a retro and prospective study of extrapyramidal side effects. Psychopharmacology (Berlin) 1996;124: 188–96.CrossRefGoogle Scholar
47Perrault, G, Schoemaker, H, Scatton, B.Place de l'amisulpride dans la ciasse des neuroleptiques atypiques. L'Encephale 1996(Suppl. 11):3–8.Google Scholar
48Rien, W, Turjanski, S. Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 1997;12(Suppl. 2):S19-27.CrossRefGoogle Scholar
49Sherr, JD, Thaker, G. Progression of abnormal involuntary movements during risperidone treatment. J Clin Psychiatry 1998;59: 478–9.CrossRefGoogle ScholarPubMed
50Simpson, G, Lee, JH, Shrivastava, RK. Clozapine in tardive dyskinesias. Psychopharmacology 1978 ,56:75-80.CrossRefGoogle Scholar
51Simpson, G. The treatment of tardive dyskinesia ad tardive dystonia. J Clin Psychiatry 2000;61(Suppl. 4):39–44.Google Scholar
52Sotullo, CA, Keck, PE, Elroy, SMC. Olanzapine in the treatment of tardive dyskinesia: A report of two cases. J Clin Psychopharmacol 1999;19(1): 100–1.CrossRefGoogle Scholar
53Speller, JC, Barnes, TRE, Curson, DA, Pantelis, C, Alberts, JL. One year, low-dose neuroletic study of inpatients with chronic schizophrenia characterised by persisten negative symptoms. Amisulpride versus Haloperidol. Br J Psychiatry 1997;171: 564–8.CrossRefGoogle Scholar
54Tamminga, CA, Thaker, GK, Moran, M, Kakigi, T, Gao, XM. Clozapine in tardive dyskinesia: observations from human and animal studies. J Clin Psychiatry 1994;55(9 Suppl. B): 120–6.Google Scholar
55Tollefson, GD, Beasley, CM, Tran, PV. (abstact)Olanzapine versus haloperidol: resulte of multicenter, international triar. Schizophr Res 1996;18:131.CrossRefGoogle Scholar
56Waddington, JL. Tardive dyskinesia in schizophrenia and other disorders: Association with aging, cognitive dysfunction, and structural brain pathology in relation to neuroleptic exposure. Hum Psychopharmacol 1987;2:11-22.CrossRefGoogle Scholar
57Woerner, MG, Sheitman, BB, Lieberman, JA, Kane, JM. Tardive dyskinesia induced by risperidone? Am J Psychiatry 1996; 153: 843.Google ScholarPubMed
58Wolf, MA, Wertenschlad, N. Facteurs de risque et prévention des dyskinésies tardives. Can J Psychiatry 1989;34: 177–81.CrossRefGoogle Scholar
59Wolf, MA, Yassa, R, Llorca, PM. Neuroleptic-induced movement disorders: historical perspectives. In: Yassa, R, Nair, NPV, Jeste, D, editors. Neuroleptic-inducted Movement Disorders: A Comprehensive Survey. Cambridge University Press; 1997. p. 3–9.Google Scholar
60Wolf, MA. Les dyskinésies tardives. Mosaique 2000; 11:5-10.Google Scholar
61Yassa, R, Jeste, DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18(4): 701–15.CrossRefGoogle ScholarPubMed